A6 | Neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques after neutralization-resistant SIVsmE543-3 infection | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
A5 | Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' between innate and adaptive immune cells in HIV controllers on ART | On-demand oral abstract session | Innate immunity |
A5 | Extracellular vehicles carrying HIV-1 Nef induce trained immunity in myeloid cells | E-poster | Innate immunity |
A5 | Robust anti-viral immune responses at the placenta during early gestation limit in utero HIV infection and replication | E-poster | Innate immunity |
A49 | Antibody responses of cows immunized with HIV V2-apex focusing immunogens | E-poster | Novel animal models to test interventions (vaccines, cure, antiretrovirals) |
A46 | Correlation between serum and salivary HIV antibodies in a cohort of well-controlled children living with perinatal HIV/AIDS | E-poster | Novel assays to measure immune responses |
A45 | Defining an adipose tissue single cell atlas to understand metabolic disease in HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
A45 | The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
A45 | Higher comorbidity and comedication burden in women and young people living with HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
A45 | Overt expression of IL-32 isoforms in the colon of ART-treated PLWH: negative regulation by IL-17A | E-poster | Co-morbidities: Non-communicable diseases |